Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents | Zendy

Tomefa E. Asempa | Zendy; David P. Nicolau | Zendy; Joseph L. Kuti | Zendy

Open Access

Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents

Author(s) -

Tomefa E. Asempa,

David P. Nicolau,

Joseph L. Kuti

Publication year - 2019

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.00535-19

Subject(s) - pseudomonas aeruginosa , carbapenem , microbiology and biotechnology , antibiotics , intensive care unit , intensive care , pathogen , biology , lactam , beta lactam , medicine , intensive care medicine , bacteria , chemistry , genetics , stereochemistry

Pseudomonas aeruginosa , a frequent pathogen in the intensive care unit (ICU), has the propensity to develop antibiotic resistance. In particular, carbapenem-nonsusceptible (NS)P. aeruginosa poses tremendous challenges, and new antibiotics will be needed to treat this phenotype. Here we determine carbapenem nonsusceptibility rates for contemporaryP. aeruginosa isolates from U.S. ICUs andin vitro activities of new β-lactam combination agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research